Generic placeholder image

New Emirates Medical Journal

Editor-in-Chief
ISSN (Online): 0250-6882

Letter to the Editor

Dubious Results of Remdisivir Ultimately in Solidarity; Diversity of Severity of Illness is Doubtful

Author(s): Seyed Mohammad Reza Hashemian*, Hamidreza Jamaati, Mostafa Norizadehtazehkand, Majid Malkmohammad, Parisa Adimi and Ali Amirsavadkouhi

Volume 2, Issue 1, 2021

Published on: 20 November, 2020

Page: [82 - 83] Pages: 2

DOI: 10.2174/0250688201999201120113151

open_access

[1]
Pan H, et al. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. WHO Solidarity trial consortium. N Engl J Med 2020.
[2]
Pasquini Z, Montalti R, Temperoni C, et al. Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU. J Antimicrob Chemother 2020; 75(11): 3359-65.
[http://dx.doi.org/10.1093/jac/dkaa321] [PMID: 32829390]
[3]
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19—preliminary report. N Engl J Med 2020; 383(19): 1813-26.
[http://dx.doi.org/10.1056/NEJMoa2007764] [PMID: 32445440]
[4]
Olender SA, Perez KK, Go AS, et al. Remdesivir for severe COVID-19 versus a cohort receiving standard of care. Clin Infect Dis 2020.ciaa1041
[http://dx.doi.org/10.1093/cid/ciaa1041] [PMID: 32706859]
[5]
Seyed MohammadReza Hashemian, Tayebeh Farhadi, Ali Akbar Velayati. A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19. Drug Des Devel Ther 2020; 14: 3215-22.
[http://dx.doi.org/10.2147/DDDT.S261154]

© 2024 Bentham Science Publishers | Privacy Policy